Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Am J Cardiol. 2013 Jun 7;112(5):720–725. doi: 10.1016/j.amjcard.2013.04.051

Figure 4.

Figure 4

The effect of treatment on World Health Organization (WHO) functional class. The percentage of patients in whom an improvement by ≥1 WHO functional class is reported at week 4, 8, and 12 for the placebo (n = 111), spironolactone (n = 21), ambrisentan (10 mg/day, n = 57), and ambrisentan + spironolactone (n = 10) treatment groups.